Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Is cancer immunotherapy a private affair?: Immune checkpoint blockade, a relatively new cancer treatment, substantially extends the survival of a subset of patients. Previous work has shown that patients whose tumors harbor the largest number of mutations—and thus produce a large number of “neoantigens” recognized as foreign by the immune system—are most likely to benefit. Expanding on these earlier studies, Van Allen et al. studied over 100 patients with melanoma and found a similar correlation (see the Perspective by Gubin and Schreiber). There was no evidence, however, that specific neoantigen sequences were shared by patients who responded. Science , this issue p. 207 , see also p. 158
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“The model achieved AUCs of 0.734, 0.729, and 0.935 at 1, 2, and 3 years, respectively (Fig. 4F).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“Cox proportional hazard regression analysis established the algorithm’s independence as a prognostic determinant following adjustment for conventional clinicopathological covariates (P < 0.001; Fig. 4G and table S1).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“it achieved an AUC of 0.989, an AUPRC of 0.993, an F1 score of 0.99, and a C-index of 0.989 (Fig. 4, A and B, and fig. S2A).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 2×
“To stratify our cohort, “clinical benefit” was defined using a composite end point of complete response or partial response to ipilimumab by RECIST criteria (21) or stable disease by RECIST criteria with overall survival greater than 1 year (n = 27).”
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“We performed somatic mutation identification (table S1) and germline human lymphocyte antigen (HLA) typing (table S2) using established methods (14, 19).”
Self-citationThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Incorporation of patient-matched RNA-level information may help prioritize putative neoantigens and elucidate possible tumor immune microenvironmental effects, including interferon-related genes and additional immune checkpoint molecules that are relevant in melanoma (28).”
Cited by
Items 901–1,000 of 1,010
Emerging Biomarkers in Cutaneous Melanoma
Eisenstein, A. S., Gonzalez, E. C., Raghunathan, R., Xu, X., Wu, M., McLean, E. O., McGee, J. S., Ryu, B., & Alani, R. M. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0318-z · Cited by 52
“Notably, high mutational load in tumor tissue has been correlated to overall survival in treatment with PD-1 inhibitors [222] and CTLA-4 inhibitors [223, 224].”
BackgroundDuan, J., Wang, Y., & Jiao, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1722 · Cited by 51
Pavlick, A. C., Fecher, L. A., Ascierto, P. A., & Sullivan, R. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_243071 · Cited by 45
Possible Biomarkers for Cancer Immunotherapy
Otoshi, T., Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2019) · Cancers · doi:10.3390/cancers11070935 · Cited by 48
Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab
Jacome, A. A. D. A., & Eng, C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1680636 · Cited by 48
“Similarly to PD-L1 expression, the cutoff to dichotomize TMB in high and low is also uncertain, with studies using both >100 [130] and ≥178 [131] nonsynonymous mutations as thresholds.”
ResultAnalysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma
Mitra, S., Lauss, M., Cabrita, R., Choi, J., Zhang, T., Isaksson, K., Olsson, H. L., Ingvar, C., Carneiro, A., Staaf, J., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12663 · Cited by 58
“…that include activity of intratumor immunological effector cells (Riaz et al., 2017; Yuan et al., 2011), tumor mutational burden (Riaz et al., 2017; Van Allen et al., 2015), mismatch repair deficiency (Le et al., 2017b; Viale et al., 2017), tumor aneuploidy (Davoli et al., 2017), PDL1 levels (Long…”
BackgroundResultDu, K., Wei, S., Wei, Z., Frederick, D. T., Miao, B., Moll, T. O. C., Tian, T., Sugarman, E. T., Gabrilovich, D. I., Sullivan, R. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26299-4 · Cited by 52
Profiling of immune features to predict immunotherapy efficacy
Ye, Y., Zhang, Y., Yang, N., Gao, Q., Ding, X., Kuang, X., Bao, R., Zhang, Z., Sun, C., Zhou, B., et al. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100194 · Cited by 52
Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
Zou, X.-L., Li, X., Ke, H., Zhang, G., Tang, Q., Yuan, J., Zhou, C.-J., Zhang, J.-L., Zhang, R., & Chen, W.-Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689076 · Cited by 52
“Type of cancer No of investigated patients Test for NAL Group Drug/treatment Result (whether NAL is associated with clinical benefit) Reference Melanoma 110 WES High/low Ipilimumab YES (62) Melanoma 38 WES High/low Pembrolizumab and nivolumab NO (63) Non–small cell lung cancer 34 WES High/low Pembrolizumab YES (6) Non…”
BackgroundMelanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Testa, U., Castelli, G., & Pelosi, E. (2017) · Medical Sciences · doi:10.3390/medsci5040028 · Cited by 59
Mutated RAS: Targeting the “Untargetable” with T Cells
Chatani, P. D., & Yang, J. C. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2138 · Cited by 46
Frigola, J., Navarro, A., Carbonell, C., Callejo, A., Iranzo, P., Cedrés, S., Martínez‐Martí, A., Pardo, N., Gonzalez, N. S., Martinez, D., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12891 · Cited by 53
Cuproptosis predicts the risk and clinical outcomes of lung adenocarcinoma
Hu, Q., Wang, R., Ma, H., Zhang, Z., & Xue, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.922332 · Cited by 49
CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Ghazi, B., El Ghanmi, A., Kandoussi, S., Ghouzlani, A., & Badou, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978195 · Cited by 46
Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 52
Meulenaere, A. D., Vermassen, T., Aspeslagh, S., Huvenne, W., Dorpe, J. V., Ferdinande, L., & Rottey, S. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.05.002 · Cited by 49
Miller, D. M., Faulkner-Jones, B. E., Stone, J. R., & Drews, R. E. (2017) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.06.005 · Cited by 46
Difference in Immunosuppressive Cells Between Peritumoral Area and Tumor Core in Glioblastoma
Tamura, R., Ohara, K., Sasaki, H., Morimoto, Y., Kosugi, K., Yoshida, K., & Toda, M. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.08.133 · Cited by 52
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 51
“with increased responses and overall survival (OS) [26, 27].”
BackgroundMendez, L., Posey, R. R., & Pandolfi, P. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01162 · Cited by 53
“High mutational/neoantigen burden correlates with response to checkpoint blockade (28, 29).”
BackgroundWang, G., Wan, H., Jian, X., Li, Y., Ouyang, J., Tan, X., Zhao, Y., Lin, Y., & Xie, L. (2020) · BioMed Research International · doi:10.1155/2020/5798356 · Cited by 52
Liu, K., Wang, Y., Zhu, Q., Li, P., Chen, J., Tang, Z., Shen, Y., Cheng, X., Lu, L., & Liu, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2736-1 · Cited by 46
Emerging Immunotherapies in the Treatment of Brain Metastases
Nieblas‐Bedolla, E., Nayyar, N., Singh, M., Sullivan, R. J., & Brastianos, P. K. (2020) · The Oncologist · doi:10.1002/onco.13575 · Cited by 52
Integrated molecular drivers coordinate biological and clinical states in melanoma
Conway, J. R., Dietlein, F., Taylor-Weiner, A. N., AlDubayan, S. H., Vokes, N. I., Keenan, T. E., Reardon, B. M., He, M. X., Margolis, C. A., Weirather, J. L., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00739-1 · Cited by 45
Self-citationThe role of opioids in cancer response to immunotherapy
Botticelli, A., Cirillo, A., Pomati, G., Cerbelli, B., Scagnoli, S., Roberto, M., Gelibter, A. J., Mammone, G., Calandrella, M. L., Cerbelli, E., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02784-8 · Cited by 51
Haddad, A. F., Young, J. S., Gill, S. A., & Aghi, M. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.019 · Cited by 50
DeepNeo: a webserver for predicting immunogenic neoantigens
Kim, J. Y., Bang, H., Noh, S.-J., & Choi, J. K. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad275 · Cited by 50
Gut microbial structural variation associates with immune checkpoint inhibitor response
Liu, R., Zou, Y., Wang, W.-Q., Chen, J.-H., Zhang, L., Feng, J., Yin, J.-Y., Mao, X.-Y., Li, Q., Luo, Z.-Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42997-7 · Cited by 45
“Several factors have been identi fi ed to affect the effectiveness of ICIs, including the tumor surface ’ s PD-L1 expression level 4 , the tumor mutational burden 5,6 , and the activity of interferon-γ pathway 7 .”
BackgroundApavaloaei, A., Zhao, Q., Hesnard, L., Cahuzac, M., Durette, C., Larouche, J., Hardy, M., Vincent, K., Brochu, S., Laverdure, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00979-2 · Cited by 57
Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions
Radvanyi, L. G. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000162 · Cited by 55
“Melanoma TILs have been found to recognize mutated neoepitopes in patients who have underwent partial and complete responses to adoptive cell therapy.(115,118,119) Mutation-specific T cells are now being isolated from peripheral blood.”
BackgroundImmunotherapy in ovarian cancer
Krishnan, V., Berek, J. S., & Dorigo, O. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.11.003 · Cited by 58
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
Duperret, E. K., Wise, M. C., Trautz, A., Villarreal, D. O., Ferraro, B., Walters, J. N., Yan, J., Khan, A. S., Masteller, E. L., Humeau, L. M. P. F., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.010 · Cited by 45
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
Clarke, J. M., George, D. J., Lisi, S., & Salama, A. K. S. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0549-7 · Cited by 46
“In fact, tumor mutational burden, known to enhance neoantigen formation, has been shown to be associated with increased response to ICBs, and in some cases improved OS as well, across tumor types such as melanoma [99, 100], NSCLC [101], and UC [54, 56, 102].”
BackgroundHomologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer
Telli, M. L., Stover, D. G., Loi, S., Aparicio, S. A. J. R., Carey, L., Domchek, S. M., Newman, L. A., Sledge, G. W., & Winer, E. P. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4807-x · Cited by 47
“Although tumor immunogenicity is hypothesized to relate to the number of ‘neoantigens,’ or tumor-specific antigens recognized as foreign, and neoantigen load has been associated with response to immune checkpoint therapies [63, 64], breast cancers have relatively few somatic mutations and inferred neoantigen load [65].”
BackgroundMolecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma
Fiorentini, C., Grisanti, S., Cosentini, D., Abate, A., Rossini, E., Berruti, A., & Sigala, S. (2019) · Journal of Oncology · doi:10.1155/2019/6072863 · Cited by 47
Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy
Ijsselsteijn, M. E., Pamplona, R. S., Hermitte, F., & de Miranda, N. F. C. C. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.003 · Cited by 54
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
Kim, H. S., Cha, H., Kim, J.-H., Park, W., Choi, Y., Sun, J., Ahn, J. S., Ahn, M., Park, K., & Lee, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.001 · Cited by 49
Na, K. J., Choi, H., Oh, H. R., Kim, Y. H., Lee, S. B., Jung, Y. J., Koh, J., Park, S., Lee, H. J., Jeon, Y. K., et al. (2020) · Theranostics · doi:10.7150/thno.48954 · Cited by 51
“To corroborate the predictive value of GLUTratio for immunotherapy response, we investigated the GLUT-ratio in another melanoma data treated with anti-CTLA4 [25].”
MethodResisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 47
Yang, H., Sun, L., Guan, A., Yin, H., Liu, M., Mao, X., Xu, H. C., Zhao, H., Lü, X., Sang, X., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02711-8 · Cited by 50
Herbert, K., Binet, R., Lambert, J.-P., Louphrasitthiphol, P., Kalkavan, H., Sesma-Sanz, L., Robles-Espinoza, C. D., Sarkar, S., Suer, E., Andrews, S., et al. (2019) · Genes & Development · doi:10.1101/gad.314633.118 · Cited by 45
“…beusefulindecisionsregardingpatientstratificationfor immunotherapy — where some studies have suggested that a high mutation load may be important (Snyder et al. 2014; Van Allen et al. 2015; Lauss et al. 2017; Morrison et al. 2018) — remains to be determined.”
Li, M., Gao, X., & Wang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1090838 · Cited by 57
“We further confirmed that the TMBPS correlated positively with OS in two lung cancer cohorts [Rizvi cohort (10) and Hellmann cohort (23)] and two melanoma cohort [Hugo cohort (11) and Allen cohort (12)] receiving the ICB therapy (Figure 3E).”
BackgroundResultTargeting neoantigens for cancer immunotherapy: Table 1.
Lu, Y., & Robbins, P. F. (2016) · International Immunology · doi:10.1093/intimm/dxw026 · Cited by 48
Targeting Immune Checkpoints in Hematologic Malignancies
Alatrash, G., Daver, N. G., & Mittendorf, E. A. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012682 · Cited by 49
“A number of studies have demonstrated better efficacy with immune checkpoint blockade in patients who have high levels of CTLA-4 and PD-1 on TIL and high expression of CTLA4 and PD-L1 ligands on the tumor cells (Taube et al., 2014; Van Allen et al., 2015; McGranahan et al., 2016).”
BackgroundPark, J., Talukder, A. H., Lim, S. A., Kim, K., Pan, K., Melendez, B., Bradley, S. D., Jackson, K. R., Khalili, J. S., Wang, J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0051 · Cited by 59
Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors
Mösch, A., Raffegerst, S. H., Weis, M., Schendel, D. J., & Frishman, D. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01141 · Cited by 45
Ozaki, Y., Muto, S., Takagi, H., Watanabe, M., Inoue, T., Fukuhara, M., Yamaura, T., Okabe, N., Matsumura, Y., Hasegawa, T., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02446-1 · Cited by 43
“Patients with higher TMB levels are more likely to benefit from immunotherapy using immune checkpoint inhibitors [12, 14, 28].”
BackgroundDeterminants of Resistance to Checkpoint Inhibitors
Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 47
Tan, Q., Wang, D., Yang, J., Xing, P., Yang, S., Li, Y., Qin, Y., He, X., Liu, Y., Zhou, S., et al. (2020) · Theranostics · doi:10.7150/thno.45816 · Cited by 48
The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy
Ahmed, M. E., Falasiri, S. S. A., Hajiran, A. J., Chahoud, J., & Spiess, P. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103334 · Cited by 53
“studied the relationship between response to CTLA-4 blockade and the genetic sequencings and mutations [90].”
BackgroundTran, N. H., Qiao, R., Xin, L., Chen, X., Shan, B., & Li, M. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-00260-4 · Cited by 50
“The potential of neoantigens for cancer 31 vaccines is supported by multiple evidences, including the correlation between mutation load 32 and response to immune checkpoint inhibitor therapies [4, 5], neoantigen-specific T cell 33 responses detected even before vaccination (naturally occurring) [6-8].”
BackgroundNoninvasive Imaging of Cancer Immunotherapy
Abousaway, O., Rakhshandehroo, T., den Abbeele, A. D. V., Kircher, M. F., & Rashidian, M. (2020) · Nanotheranostics · doi:10.7150/ntno.50860 · Cited by 45
“Clinical studies using patient samples have correlated CTLA-4 expression of tumor-infiltrating T cells to ipilimumab response in melanoma using whole-exome RNA sequencing, and in NSCLC patients through IHC staining of tumor sections [132,133].”
BackgroundActivity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
Glutsch, V., Kneitz, H., Gesierich, A., Goebeler, M., Haferkamp, S., Becker, J. C., Ugurel, S., & Schilling, B. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02832-0 · Cited by 49
Self-citationMolecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
Vukadin, S., Khaznadar, F., Kizivat, T., Včev, A., & Smolić, M. (2021) · Biomedicines · doi:10.3390/biomedicines9070835 · Cited by 49
“is the rationale for the widespread use of ICI in their treatment [4,28,29].”
BackgroundReardon, B. M., Moore, N. D., Moore, N., Kofman, E. R., AlDubayan, S. H., Cheung, A. T. M., Conway, J. R., Elmarakeby, H., Imamović, A., Kamran, S. C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00243-3 · Cited by 50
Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer
Rosellini, P., Amintas, S., Caumont, C., Veillon, R., Galland-Girodet, S., Cuguillière, A., Nguyen, L., Domblides, C., Gouverneur, A., Merlio, J.-P., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.026 · Cited by 44
QDPR deficiency drives immune suppression in pancreatic cancer
Liu, J., He, X., Deng, S., Zhao, S., Zhang, S., Chen, Z., Xue, C., Zeng, L., Zhao, H., Zhou, Y., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.015 · Cited by 48
Chen, D., Jin, Z., Han, C., Wu, Y., Bian, Y., Yuan, T., Lv, H., Xia, Q., Wang, L., Chu, Q., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.014 · Cited by 51
Emerging role of immunotherapy in urothelial carcinoma—Advanced disease
Zibelman, M. R., Ramamurthy, C., & Plimack, E. R. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.10.017 · Cited by 47
Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer
Tan, Y. S., Sansanaphongpricha, K., Prince, M. E., Sun, D., Wolf, G. T., & Lei, Y. L. (2018) · Journal of Dental Research · doi:10.1177/0022034518764416 · Cited by 46
Identifying neoantigens for use in immunotherapy
Hutchison, S., & Pritchard, A. L. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9771-6 · Cited by 43
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Bucktrout, S. L., Bluestone, J. A., & Ramsdell, F. (2018) · Genome Medicine · doi:10.1186/s13073-018-0588-4 · Cited by 50
Wu, Z., Wang, M.-R., Liu, Q., Liu, Y., Zhu, K., Chen, L., Guo, H., Li, Y., & Shi, B. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.39056 · Cited by 47
Chumsri, S., Sokol, E. S., Soyano‐Muller, A. E., Parrondo, R. D., Reynolds, G. A., Nassar, A., & Thompson, E. A. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7543 · Cited by 49
Butner, J. D., Wang, Z., Elganainy, D., Feghali, K. A. A., Plodinec, M., Călin, G. A., Dogra, P., Nizzero, S., Ruiz-Ramírez, J., Martin, G. V., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00662-0 · Cited by 46
Liao, J.-Y., & Zhang, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.663264 · Cited by 48
“Recent studies have shown that somatic mutation, neoantigen burden and neoantigen density associated with long-term benefit from immune checkpoint inhibitors in several solid tumors, which indicated that more mutation-associated neoantigens may enhance the immunogenicity and improve immune responses of ICIs (19, 44, 8…”
BackgroundSenescence and Immunoregulation in the Tumor Microenvironment
Ruhland, M. K., & Alspach, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.754069 · Cited by 52
Cancer Immunotherapy: Whence and Whither
Stambrook, P. J., Maher, J. F., & Farzaneh, F. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0427 · Cited by 46
“These neoantigens can likely contribute to recognition by tumor-reactive T cells (160) when unleashed by inhibition of immune blockade (161, 162), suggesting that a heavier mutation load may predict a more successful outcome following inhibition of a PD-1 or CTLA-4 blockade.”
BackgroundPark, J. C., Krishnakumar, H. N., & Saladi, S. V. (2022) · Current Oncology · doi:10.3390/curroncol29060334 · Cited by 49
“In melanoma patients, neoantigen load was found to be significantly associated with the clinical benefit of ipilimumab [60].”
BackgroundChen, D., Liu, P., Lu, X., Li, J., Qi, D., Zang, L., Lin, J., Liu, Y., Zhai, S., Fu, D., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03042-7 · Cited by 57
“…assess the predictive performance of LM.SIG, including 5 SKCM cohorts (Liu SKCM [24], Gide SKCM [25], Riaz SKCM [26], Hugo SKCM [27] and Van SKCM [28]), 1 Renal Cell Carcinoma (RCC) cohort (Bruan RCC [29]), 1 Urothelial Carcinoma (UC) cohort (Mariathasan UC [30]), 1 GBM cohort (Zhao GBM [31]), 1…”
BackgroundMolecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Jenkins, R. W., Thummalapalli, R., Carter, J., Cañadas, I., & Barbie, D. A. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-060116-022926 · Cited by 43
Immunotherapy in genitourinary malignancies
Mehta, K. D., Patel, K., & Parikh, R. A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0457-4 · Cited by 46
“The investigators noted that mutational load, neoantigens, and expression of cytolytic markers were predictive markers associated with clinical benefit to ipilimumab [62, 63].”
BackgroundA method to reduce ancestry related germline false positives in tumor only somatic variant calling
Halperin, R. F., Carpten, J. D., Manojlovic, Z., Aldrich, J., Keats, J. J., Byron, S. A., Liang, W. S., Russell, M., Enríquez, D., Claasen, A. M., et al. (2017) · BMC Medical Genomics · doi:10.1186/s12920-017-0296-8 · Cited by 43
“Recent data shows the importance of mutational burden as it correlates to the response to immune checkpoint blockade therapies [35].”
BackgroundBräunlein, E., & Krackhardt, A. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01702 · Cited by 42
“However, subsequent studies could not confirm a prevalent role of such a defined peptide motif (22, 30).”
BackgroundChen, B., Li, L., Li, M., & Wang, X. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00534-4 · Cited by 46
“As yet, however, the success of immunotherapy has remained limited to a relatively small proportion of cancer patients [9].”
BackgroundBiological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
Olbryt, M., Rajczykowski, M., & Widłak, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114071 · Cited by 47
Alkallas, R., Lajoie, M., Moldoveanu, D., Hoang, K. V., Lefrançois, P., Lingrand, M., Ahanfeshar-Adams, M., Watters, K. A., Spatz, A., Zippin, J. H., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0077-8 · Cited by 44
Yan, C., Li, K., Meng, F., Chen, L., Zhao, J., Zhang, Z., Xu, D., Sun, J., & Zhou, M. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.04.006 · Cited by 47
Martin, S. D., Wick, D. A., Nielsen, J. S., Gierc, N. S., Holt, R. A., & Nelson, B. H. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1371895 · Cited by 45
Blake, Z., Marks, D. K., Gartrell, R. D., Hart, T. D., Horton, P., Cheng, S. K., Taback, B., Horst, B. A. J., & Saenger, Y. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0338-6 · Cited by 43
“For ipilimumab, an increase in tumorinfiltrating lymphocytes (TILs) as well as a high genomic mutational load have been shown to be predictive of response to therapy [27, 28].”
BackgroundNovel biomarkers in multiple myeloma
Levin, A., Hari, P., & Dhakal, B. (2018) · Translational research · doi:10.1016/j.trsl.2018.05.003 · Cited by 48
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
Miura, Y., & Sunaga, N. (2018) · Cancers · doi:10.3390/cancers10080245 · Cited by 41
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy
Rizk, E. M., Gartrell, R. D., Barker, L. W., Esancy, C. L., Finkel, G. G., Bordbar, D. D., & Saenger, Y. M. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.005 · Cited by 47
Varn, F. S., Schaafsma, E., Wang, Y., & Cheng, C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1342 · Cited by 61
“Given that high immune infiltration and low TCRdiversity have bothbeen associatedwith response to immune checkpoint blockade (14, 51), our analyses suggest that EBVpositive cancers may represent good targets for future immunotherapeutic approaches.”
BackgroundWu, H., Wang, Z., Zhao, Q., Wang, F., & Xu, R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0681-2 · Cited by 42
The Current Lung Cancer Neoantigen Landscape and Implications for Therapy
Ye, L., Creaney, J., Redwood, A., & Robinson, B. W. S. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1624 · Cited by 44
Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers
Zhang, P., & Huang, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01050-0 · Cited by 45
Aamdal, E., Inderberg, E. M., Ellingsen, E. B., Rasch, W., Brunsvig, P. F., Aamdal, S., Heintz, K., Vodák, D., Nakken, S., Hovig, E. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663865 · Cited by 46
“Clinical benefit from ipilimumab is associated with high tumor mutational burden (3) (TMB) and a high number of predicted neoantigens (4, 5).”
BackgroundCTLA-4 Expression and Its Clinical Significance in Breast Cancer
Kern, R., & Panis, C. (2021) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-021-00618-5 · Cited by 44
Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
Zheng, Y., Fu, Y., Wang, P., & Ding, Z. (2022) · Disease Markers · doi:10.1155/2022/8270305 · Cited by 43
“Studies have proven that MSI-H CRC patients have a higher survival rate and therapeutic effectiveness following immune checkpoint inhibitor therapy [5, 6, 89, 90].”
BackgroundKim, J. H., Ryu, M., Park, Y. S., Ma, J., Lee, S., Kim, D., & Kang, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09488-2 · Cited by 45
Zhang, P., Liu, J.-L., Pei, S., Wu, D., Xie, J., Liu, J., & Li, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1189520 · Cited by 48
“Immunophenoscores (IPS) were retrieved from the Cancer Immunome Atlas (TCIA) database for LUAD (27).”
MethodMaekawa, S., Takata, R., & Obara, W. (2024) · Cancers · doi:10.3390/cancers16030523 · Cited by 55
Prioritization schema for immunotherapy clinical trials in glioblastoma
Hodges, T. R., Ferguson, S. D., Caruso, H. G., Kohanbash, G., Zhou, S., Cloughesy, T. F., Berger, M. S., Poste, G. H., Khasraw, M., Ba, S., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1145332 · Cited by 41
“, anti-CTLA-4, anti-PD-1/PD-L1 antibodies) in melanoma and non-small cell lung carcinoma.(116-118) The accumulation of somatic mutations in D ow nl oa de d by [ U ni ve rs ity o f Pe nn sy lv an ia ] at 1 8: 01 2 3 Fe br ua ry 2 01 6”
BackgroundMutation Drivers of Immunological Responses to Cancer
Porta-Pardo, E., & Godzik, A. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0233 · Cited by 40
“determining the immunogenicity of a tumor and can be used in clinical settings to try to personalize immune-based therapy (6, 32, 33), few analyses have focused on whether cancer somatic mutations can influence host immune response through other means.”
Laban, S., Giebel, G., Klümper, N., Schröck, A., Doescher, J., Spagnoli, G., Thierauf, J. C., Theodoraki, M., Remark, R., Gnjatic, S., et al. (2017) · OncoTarget · doi:10.18632/oncotarget.14830 · Cited by 37
Budczies, J., Bockmayr, M. L., Klauschen, F., Endris, V., Fröhling, S., Schirmacher, P., Denkert, C., & Stenzinger, A. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22468 · Cited by 43
Inhibitors of ER Aminopeptidase 1 and 2: From Design to Clinical Application
Georgiadis, D., Mpakali, A., Koumantou, D., & Stratikos, E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180214111849 · Cited by 39
Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
Sahu, A. D., Lee, J. S., Wang, Z., Zhang, G., Iglesias‐Bartolomé, R., Tian, T., Wei, Z., Miao, B., Nair, N. U., Ponomarova, O., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188323 · Cited by 42
“Cross-validation accuracy of SR-based supervised predictors in predicting resistance to PD 1 (Hugo et al , 2016 ; Prat et al , 2017 ) and CTLA 4 blockade (Van Allen et al , 2015 ), reported in terms of the corresponding receiver operating characteristic (ROC) curves.”
MethodThe Discovery of Biomarkers in Cancer Immunotherapy
George, A. P., Kuzel, T. M., Zhang, Y., & Zhang, B. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.015 · Cited by 45
“published a study of melanoma patients treated with ipilimumab and discovered that the presence of granzyme A and perforin, two cytolytic factors in the tumor microenvironment, were also associated with improved clinical response [27].”
Background
Metadata
- Authors
- Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., Utikal, J., Hassel, J. C., Weide, B., Kaehler, K. C., Loquai, C., Mohr, P., Gutzmer, R., Dummer, R., Gabriel, S., Wu, C. J., Schadendorf, D., & Garraway, L. A.
- Affiliations
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- The Netherlands Cancer Institute (NL)
- Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
- University Hospital Zurich (CH)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Universitätsklinikum Tübingen (DE)
- University Hospital Schleswig-Holstein (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Elbe Kliniken Stade-Buxtehude (DE)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Miao, Diana
- Schilling, Bastian
- Schadendorf, Dirk
- Garraway, Levi A.
- ORCID
- Venue
- Science
- Published
- 2015-10-09
- Volume
- 350
- Issue
- 6257
- Pages
- 207-211
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5054517
- OpenAlex
- W2107429737
- Cited by
- 2,839
- References
- 42
- Citations by year
- 2026: 106 · 2025: 187 · 2024: 236 · 2023: 308 · 2022: 313 · 2021: 348 · 2020: 327 · 2019: 274 · 2018: 270 · 2017: 248 · 2016: 207 · 2015: 12
- FWCI
- 107.45
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- NIH (U54 HG003067)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, CTLA-4 blockade, ipilimumab, immune checkpoint inhibitors, tumor mutational burden, neoantigens, tumor microenvironment, predictive biomarkers, treatment response, exome sequencing, transcriptome, germline mutations
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antigens, Neoplasm, DNA Mutational Analysis, Female, HLA Antigens, Humans, Male, Melanoma, Middle Aged, Mutation, Skin Neoplasms, Cohort Studies, Drug Resistance, Neoplasm, Genomics, Biomarkers, Pharmacological, Young Adult, Tumor Microenvironment, Cell Cycle Checkpoints, Exome, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.